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Summary:  
 
 
Cirrhosis secondary to non-alcoholic steatohepatitis (NASH) is a common 
indication for liver transplant. In comparison to other cirrhotic patients, patients 
with NASH cirrhosis are more likely to be older and have the metabolic 
syndrome. Pre-transplant, patients require careful evaluation of cardiovascular 
risk. 
 
As the incidence of non-alcoholic fatty liver disease (NAFLD) is rising, a greater 
proportion of donor grafts have steatosis greater than 30%, which is associated 
with poor outcomes. Grafts with steatosis greater than 60% are unsuitable for 
transplant. 
 
Overall, post-transplant survival outcomes for patients with NASH cirrhosis are 
similar to those with cirrhosis without NASH. However, NASH cirrhosis is 
associated with a higher 30-day mortality, predominantly from an increase in 
cardiovascular events and infections.  
 
Following liver transplant, there is a significant risk of NASH recurrence, 
although this seldom results in allograft loss. Furthermore, a significant number 
of patients who had a liver transplant for other reasons develop NASH de novo.  
 
When patients with NASH cirrhosis are considered for transplant, one of the 
major challenges lies in identifying which patients are too high risk for surgery. 
This review aims to provide information to aid this decision making process, and 
to provide guidance on the peri-operative care strategies that can modify risk. 
 
Introduction  
 
NAFLD is common with an estimated global prevalence of 25% [1].  NAFLD 
encompasses a spectrum of pathology; whilst most patients have simple 
steatosis, around 7-30% have NASH, of which 10-20% progress to liver cirrhosis, 
for which the only treatment is liver transplantation [1].   
 
Risk factors for NAFLD include the metabolic syndrome [1], increasing age and 
genetic polymorphisms, such as the patatin-like phospholipase domain-
containing 3 (PNPLA3) gene variant I148M [2, 3]. The metabolic syndrome 
represents a collection of cardiovascular risk factors associated with insulin 
resistance such as central obesity, hypertension, dyslipidaemia and glucose 
intolerance/diabetes.  Around 80% of patients with NAFLD have at least one 
component of the metabolic syndrome, with the likelihood of having NAFLD 
rising in proportion with the number of metabolic syndrome components 
present [4]. In high risk populations, such as the morbidly obese and patients 
with diabetes, the prevalence of NAFLD is reported to be 70-90% [5, 6].   
 
As the incidence of obesity and diabetes is rising, so too is the incidence of 
NAFLD [7]. The proportion of liver transplants performed for NASH cirrhosis has 
increased from 1.2% in 2001 to 9.7% in 2009 [8], with NASH now the second 
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leading aetiological indication for liver transplant in the US [9], and is predicted 
to become the most common indication for transplant within the next 20 years 
[8]. 
 
 
Studies assessing the impact of NAFLD on mortality have shown mixed results. 
This may reflect variation in the inclusion criteria (deranged liver function tests 
vs ultrasound findings vs biopsy results), failure to account for NAFLD severity, 
and varying degrees of adjustment for confounding variables such as diabetes 
and obesity. In a meta-analysis, the adjusted hazard ratio (HR) for overall 
mortality in NAFLD compared to patients without NAFLD was 1.04 (95% 
confidence interval (CI) 1.03-1.04) [1], and thus whilst steatosis alone may not 
have a major impact on mortality risk, the degree of associated fibrosis does 
influence outcomes. Angulo et al performed retrospective analysis of laboratory 
and histological data on 691 patients diagnosed with NAFLD. The results showed 
that mortality risk was related to the degree of fibrosis, regardless of 
steatohepatitis or NAFLD activity (stage 1 HR 1.88 (95% CI 1.28-2.77), stage 2 
HR 2.89 (95% CI 1.93-4.33), stage 3 HR 3.76 (,95% CI 2.40-5.89), stage 4 HR 10.9 
(95% CI 6.06-19.62) [10] 
 
In patients requiring liver transplantation, the increased prevalence of the 
metabolic syndrome in NAFLD complicates their operative work-up and will be 
reviewed in this article alongside their transplant outcome data. Notably, some 
patients with NAFLD develop recurrent disease after transplantation, alongside a 
proportion of non-NAFLD patients that develop de novo NAFLD post-transplant.  
 
In evaluating the data, two issues need to be considered. Firstly, NAFLD is a 
recently recognised entity and thus there is a paucity of long-term longitudinal 
follow-up data following transplantation, in comparison with other causes of 
liver cirrhosis. Secondly, it is difficult to obtain complete incidence and 
prevalence data for NAFLD, as by the time some NAFLD patients develop 
cirrhosis, many patients lose the typical histological features of NASH. Therefore, 
some cases of NASH cirrhosis are labelled as cryptogenic cirrhosis [11].   
 
2. Pre-transplant considerations: 
 
2.1 Indications for transplant 
 
Liver transplant is an effective treatment for end-stage liver disease, with an 
overall one-year survival of around 91% and three-year survival of around 80% 
[12]. There are no disease-specific indications for transplantation in NAFLD; 
guidelines recommend that NAFLD patients be considered for liver transplant if 
they have evidence of NASH cirrhosis with end-stage liver disease or 
hepatocellular cancer [13]. The Model for End Stage Liver Disease (MELD) score 
can be used to evaluate disease severity in potential transplant candidates with 
NAFLD, similarly to cirrhosis from other causes.  
 
The diagnosis of NASH cirrhosis is ideally obtained on histology, however, liver 
biopsy may not always be possible, for example in patients presenting with 
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decompensation.  In that situation, if there is no other likely cause for cirrhosis, 
patients can be presumed to have NASH cirrhosis if they have three or more 
components of the metabolic syndrome[14]. 
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2.2 Pre-operative risk stratification 
 
2.2.1 NAFLD and cardiovascular disease (CVD) 
 
Patients with NAFLD commonly have risk factors for CVD, including diabetes, 
hypertension, hyperlipidaemia and obesity [4, 15]. Further evidence links 
NAFLD to subclinical and clinical CVD. For example, it is associated with 
endothelial dysfunction, increased carotid artery intima thickness, increased 
arterial stiffness and elevated coronary calcium scores, coronary artery disease 
(CAD), aortic valve sclerosis and cardiac arrhythmias, such as atrial fibrillation 
[16-21]. The association of NAFLD with CAD may be secondary to endothelial 
dysfunction, a pro-atherogenic lipid profile, and/or unstable coronary artery 
plaques [22-24].  Furthermore, NAFLD is associated with myocardial 
dysfunction, a reduced ability to increase heart rate and cardiac output in 
response to stress, and an increased baseline cardiac output, resulting in cardiac 
hypertrophy (“cirrhotic cardiomyopathy”)[25, 26]. Longitudinal studies suggest 
that cardiovascular disease is the most common cause of death in NAFLD [19, 
27-30] 
 
Approximately 27% of liver transplant candidates have undetected underlying 
CVD, and patients with CAD undergoing transplant have a one-year mortality 
exceeding 40% [31, 32].  Evaluation of cardiovascular risk in patients with NASH 
is important to identify which patients are likely to have poor postoperative 
outcomes and thus be unsuitable for transplant (Figure 1). It also allows the 
opportunity for pre-operative optimisation of cardiovascular risk factors. Risk 
evaluation includes history taking and examination to elicit signs and symptoms 
of coronary artery disease, and cardiovascular risk factors. All patients should 
undergo 12-lead electrocardiography (ECG), a chest X-ray (CXR) and a 
transthoracic echocardiogram (ECHO), to identify any underlying structural 
heart disease, left ventricular dysfunction and pulmonary hypertension [13]. 
Patients should also have an assessment of their functional capacity. Functional 
capacity reflects a patient’s ability to perform aerobic work and is defined by the 
maximal oxygen uptake (V02max) when the patient is physically exhausted. 
Functional capacity is usually expressed in multiples of metabolic equivalents 
(METs), where 1 MET represents the resting energy expenditure, usually around 
3.5ml oxygen/kg/min. Prior to major surgery, patients should ideally be able to 
perform >4 METs, which is roughly equivalent to climbing one flight of stairs 
without stopping. In clinical practice, this can be estimated using pulse oximetry 
following a witnessed climb of stairs, or a validated questionnaire, such as the 
Duke Activity Status Index [33]. More accurate results can be obtained using 
cardiopulmonary exercise testing (CPEX) with a cycle ergometer [34]. 
 
Following these baseline tests, in patients with suspected CAD, non-invasive 
testing can be used to decide on the need for a coronary angiogram (Figure 1). As 
patients with advanced liver disease may not be able to achieve maximal heart 
rate on exercise testing, American guidelines recommend dobutamine stress 
ECHO (DSE) testing instead in patients with suspected occult coronary 
disease[35]. However, studies suggest that, although widely used, DSE has a low 
predictive value for obstructive CAD on angiography [36, 37]. Nuclear perfusion 
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imaging also has a low positive predictive value for lesions on angiogram, and 
the use of drugs such as adenosine is potentially unsafe given the haemodynamic 
abnormalities associated with end stage liver failure [38]. Measurement of 
coronary calcium on computerised tomography (CT) is another non-invasive 
technique for estimating the degree of coronary plaque, and thus assessing 
cardiovascular risk. A ‘calcium score’ over 400 represents ‘high risk’ for 
cardiovascular events, and such patients may merit coronary angiography [39-
41]. Low calcium scores can help to exclude significant CAD. Further studies are 
needed to determine its’ cost-effectiveness in comparison with stress ECHO in 
liver transplant candidates.  
  
Quantifying cardiovascular risk using stratification scores can potentially be 
used with non-invasive testing to decide on the appropriateness of angiography. 
The Framingham Risk Score is a well-established scoring system for predicting 
10-year risk of angina, myocardial infarction and cardiac death. However, in end-
stage liver disease patients this score is thought to underestimate risk [42]. 
Furthermore, the score was based on studies in an almost exclusively Caucasian 
population in America, and so it is unclear if the results can be extrapolated. 
Guckelberger et al used receiver operation characteristic (ROC) curve analysis to 
compare different cardiovascular risk scoring systems in liver transplant 
recipients. The Prospective Cardiovascular Munster Study (PROCAM) score was 
found to be better than the European Systematic Coronary Risk Evaluation 
(SCORE) and the Framingham Risk score (FRS) in distinguishing patients with 
high and low cardiovascular risk [43]. The variables considered in this scoring 
system were gender, age, low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol, diabetes mellitus, smoking status, and family history of 
coronary artery disease. However, in their study over half of the patients were 
excluded from the analysis, which could potentially have biased the results, and 
there were few cardiovascular events overall. Therefore more studies are 
required before the widespread use of the PROCAM score can be advocated. 
 
There are several additional scoring systems to estimate peri-operative cardiac 
risks but these have not been studied in liver transplant patients. The revised 
cardiac index includes six items- four relate to the patient’s past medical history 
(CAD, heart failure, cerebrovascular disease, and diabetes mellitus), one relates 
to the risk of the planned procedure, and one relates to the creatinine level. This 
score can predict complications such as myocardial infarction, pulmonary 
embolism, complete heart block, ventricular fibrillation and cardiac arrest [44]. 
Use of troponin T measurements in conjunction with this score can improve risk 
stratification [45].  
 
Once CAD is suspected or confirmed, there are medical and surgical management 
options.  In patients with risk factors for CVD, initiation of cardioselective beta-
blockers and statins prior to major surgery is effective in reducing cardiac 
mortality and myocardial infarction [46, 47]. Carvedilol has been shown to be 
better than other beta-blockers in reducing portal pressures, and therefore may 
be the drug of choice in end-stage liver disease [48, 49]. Use of beta-blockers in 
refractory ascites has been questioned recently due to a concern that they may 
increase mortality, although there is no clear consensus at this stage[50-52]. In 
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patients undergoing non-cardiac surgery, statins have been shown to reduce 
cardiovascular mortality by 44%, and their effects may be independent of their 
ability to lower cholesterol and driven by an anti-inflammatory effect and 
platelet modulatory function [53-55]. Simvastatin and atorvastatin interact with 
calcineurin inhibitors, whereas rosuvastatin has minimal interactions and is 
relatively more potent so would therefore be preferred choice of statin [56]. 
Studies of peri-operative statin and beta-blocker use in the context of liver 
transplantation are lacking. 
 
Current American Guidelines recommend intervention for >70% stenosis on 
coronary angiography [35], yet it remains unproven whether this is the optimal 
‘cut off’ for intervention.  Yong et al found that in 21 patients with CAD who 
underwent liver transplant, those with multi-vessel disease (regardless of the 
degree of stenosis) had significantly higher mortality and post-operative length 
of stay than patients without multi-vessel disease (27% vs 4%) [57].  
 
There are reports of coronary artery bypass grafting (CABG) being performed in 
patients awaiting liver transplant [58-60], but it is generally contraindicated in 
end-stage liver failure, as it can trigger decompensation of liver disease 
secondary to release of inflammatory mediators [61, 62]. In a case series of 27 
patients, one-year survival following CABG was 80% in Child Pugh A, 45% in 
class B, and 16% in class C [63].  Small studies have shown percutaneous 
coronary intervention (PCI) in to be safe and feasible in end-stage liver disease 
[64], although these patients are at higher risk of bleeding complications [65]. In 
patients requiring coronary stenting, a bare metal stent may be preferable to 
avoid prolonged dual antiplatelet therapy, in view of the bleeding risks in liver 
failure and potential hepatotoxicity of clopidogrel [66].  
 
Whether revascularisation prior to liver transplant actually alters outcomes 
remains contentious. In a cohort study of patients undergoing liver transplant, 
those with known CAD had a cardiac mortality of 50% over a 10 year follow up, 
despite pre-transplant intervention with CABG or PCI [67]. Similar findings were 
reported by Plotkin et al [58]. However, both studies were retrospective, with 
small sample sizes, and groups were not stratified according to CAD severity. 
Furthermore, relatively few of the patients underwent angiography, and so 
authors may have underestimated the presence of occult CAD in the ‘no 
intervention’ groups. Other studies have reported a possible beneficial effect of 
intervention; in a retrospective study of 630 patients by Wray et al, there was no 
difference in mortality between those with coronary artery stenosis >50% 
(n=151), and those without significant coronary artery stenosis (n=479), with 
current CAD treatment strategies applied pre-operatively [68]. Maddhur et al 
found a reduction in 1-year post-operative mortality rates over a ten year period, 
which coincided with an increase in the number of PCI procedures performed, 
although this could be affected by other confounding variables [31]. Ideally 
randomised controlled trials would be needed to confirm whether 
revascularisation prior to transplant improves outcomes. 
 
Echocardiograms (ECHO) may identify sub-clinical abnormalities such as 
valvular disease, left ventricular dysfunction and pulmonary hypertension [13]. 
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Symptomatic valvular disease is a contraindication to transplant, although pre-
transplant left ventricular dysfunction is not an absolute contraindication to 
transplant, as it may improve post-operatively. However, it is important to 
ensure that such patients are on optimal medical therapy, including beta-
blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers (ARBs) [69]. In patients with concomitant renal dysfunction, 
these drugs should be used with caution. Patients with echocardiographic 
evidence of pulmonary hypertension should undergo right heart catheterisation 
to confirm the diagnosis. Those with moderate-severe pulmonary hypertension 
diagnosed on right heart catheterisation (mean pulmonary artery pressure≥ 
25mmHg, pulmonary capillary wedge pressure ≤ 15mmHg and pulmonary 
vascular resistance of >3 Wood units) should be referred to a cardiologist. 
Repeat right heart catheterisation after a trial of pulmonary vasodilators may 
show improvement in parameters such that liver transplantation can proceed. 
Intra-operative monitoring of the liver transplant patient should include ECG, 
pulse oximetry and monitoring of blood pressure and cardiac output. 
 
2.2.2 NAFLD and renal disease 
 
NAFLD is an independent risk factor for renal disease [70]; compared to patients 
without NAFLD, patients with NAFLD have higher creatinine levels at baseline, 
and are more likely to develop stage III kidney disease after liver transplant 
(31% vs 8%)[8, 71, 72]. Renal impairment is one of the strongest predictors of 
post-transplant cardiovascular mortality and so is important to screen for [73]. 
 
Management of renal dysfunction in liver transplant candidates is discussed in 
an excellent article by Weber et al [74]. Patients with liver cirrhosis have lower 
serum creatinine levels than those without cirrhosis, which may relate to 
reduced creatinine production by the liver, or lower muscle mass for example 
[75]. However, creatinine measurement is widely available and inexpensive and 
therefore initial screening tests should include serum creatinine, urinalysis, 
quantitative protein measurement and renal ultrasound. If these tests are 
abnormal, measurement of glomerular filtration rate (GFR) using isotopes may 
be helpful to give a better idea of the true GFR [74]. If it is indeed low, kidney 
biopsy may help to determine the underlying aetiology. 
 
In some patients, simultaneous liver-kidney (SLK) transplant may be performed. 
In patients who are not on dialysis pre-transplant, and have a serum creatinine 
<2mg/dL, SLK confers no additional survival benefit at 3 years over liver 
transplant alone (69.9% vs 69.8%) [76]. Following a consensus conference on 
SLK transplantation, it was suggested that SLK transplants are appropriate in (1) 
patients with end stage renal disease requiring a liver transplant (2) patients 
with acute kidney injury (serum creatinine >2mg/dL) on dialysis for over eight 
weeks (3) patients with chronic kidney disease with >30% interstitial fibrosis or 
>30% global glomerulosclerosis on renal biopsy [77].  Data between 2002 and 
2011 from the United Network of Organ Sharing Database (UNOS) shows that 
NASH is the most rapidly growing indication for SLK transplantation [78], 
although outcomes are poor with a 1.5 fold higher risk of kidney graft loss than 
in patients having SLK for cholestatic or alcoholic liver disease [78]. 
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2.2.3 NAFLD and obesity 
 
 
Amongst obese patients, the estimated prevalence of NASH is 57-74% [79]. 
Obesity has many implications for patients with NASH cirrhosis undergoing 
transplant. In a study of over 29,000 patients, Segev et al found that obese 
patients on the liver transplant waiting list waited longer, and were more likely 
to be passed over [80], a finding seen in many other studies [81-83]. Obese 
patients also find more difficulty in sourcing appropriate living donors as a graft 
weight to recipient weight ratio of 0.8 is commonly advocated [84, 85] 
 
The association of obesity with hypertension, diabetes, high cholesterol and 
sedentary lifestyle confers a 4.6 fold increased cardiovascular risk in such 
patients, making cardiovascular risk evaluation particularly important in this 
group [86]. Moreover, obese patients are more likely to have obstructive sleep 
apnoea, restrictive lung disease and thromboembolic disease, all of which 
increase risk of pulmonary hypertension. 
 
Obese patients should be assessed by a dietician. When calculating BMI, it is 
important to correct for ascites volume as Leonard et al found that this 
correction resulted in a lower BMI classification for 11-20% of their patients 
[87]. Moreover, despite appearing obese, many patients awaiting liver transplant 
will have protein calorie malnutrition, which is associated with reduced graft 
and patient survival [88]. In a retrospective cohort study of 207 cirrhotic 
patients undergoing liver transplantation, Carias et al found that obesity was an 
independent predictor of pre-transplant sarcopenia (p-0.0001), and patients 
with NASH cirrhosis had a six-fold increased risk of sarcopaenic obesity 
compared to patients with other causes of cirrhosis [89]. Sometimes pre-
operative weight loss is recommended in patients with compensated cirrhosis, 
however in view of the risk of protein-calorie malnutrition, it should not be 
routinely recommended in those with decompensated cirrhosis. If weight loss is 
attempted, it should only be under the close supervision of a dietician, and 
weight loss should not exceed 1kg per week [13]. 
 
The impact of obesity on patient survival and graft function after liver transplant 
remains uncertain (Table 1), with conflicting data in the literature possibly a 
reflection of selection bias as such patients have undergone rigorous evaluation 
prior to listing. Nair et al studied UNOS data from 18,172 patients, and found that 
in comparison to non-obese patients, morbid obesity (>40kg/m2) was associated 
with a greater incidence of primary graft non-function, and higher mortality 
immediately post-transplant and at 1, 2 and 5 years afterwards, predominantly 
from cardiovascular causes [90]. However, other studies have reported that an 
elevated BMI does not confer an increased mortality risk and that the greatest 
concern relates to patients with low BMI [91-93]. The studies are generally small 
cohort studies, which differ for example in whether they distinguish between 
obese and morbidly obese patients. Furthermore, using BMI alone it is unclear 
which of patients in the studies had sarcopaenic obesity. It is likely that obesity 
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contributes to operative risk, but the challenge remains the quantification of that 
risk when summated with other risk factors, not least of which is the use of 
marginal grafts. Therefore, patients with obesity pre-transplant require careful 
evaluation and arbitrary cut-off values of BMI should be avoided. 
 
Some studies have considered the role of bariatric surgery for patients 
undergoing liver transplant. Bariatric surgery could potentially be performed 
before, during or after the liver transplant. If bariatric surgery is performed 
before or after the transplant it would mean that the patient has to undergo two 
operations.  Before the transplant, the operation would be challenging because of 
the concomitant coagulopathy and portal hypertension, however, achieving 
significant weight loss prior to transplant may confer eligibility for transplant in 
patients for whom it was previously contraindicated. After liver transplant, 
bariatric surgery would be technically challenging due to the presence of 
adhesions from the first operation, and because the patients will be taking 
immunosuppression, they have an increased risk of infection. Bariatric surgery 
at the time of liver transplant is feasible but there remain concerns about the 
combination of operations, sepsis and the availability of a specialist bariatric 
team.  
 
The choices for bariatric surgery include a gastric bypass procedure, sleeve 
gastrectomy and gastric banding.  In a small study, gastric bypass after liver 
transplant was associated with improved glycaemic control in patients with 
diabetes, achievement of weight loss, and improved lipid profile [94]. However, 
gastric bypass is associated with the dumping syndrome, and malabsorption, 
which may affect immunosuppressant medications. Furthermore, following liver 
transplant, some patients may require a Roux-en-Y enteric anastomosis and 
therefore use of non-bypass procedure is preferred. Gastric bands are relatively 
non-invasive, and therefore the peri-operative risk may be reduced, although 
they introduce a potential source of infection in an immunosuppressed group, 
are relatively less effective at achieving weight loss and have a surgical revision 
rate up to 60% [95]. Sleeve gastrectomy involves no foreign body, causes 
minimal malabsorption problems and is effective at achieving weight loss, 
rendering it the procedure of choice. 
 
In a small study, seven patients with BMI>35 underwent combined liver 
transplant and sleeve gastrectomy at the time of surgery. This approach was 
deemed to be successful at achieving weight loss, and was associated with fewer 
metabolic complications after liver transplant in comparison to those who did 
not have gastric surgery [96]. Sleeve gastrectomy performed after liver 
transplant has also been shown to be effective at reducing weight and incidence 
of metabolic complications [97], but these studies have involved only small 
numbers of patients, making it difficult to draw definitive conclusions. An 
American study looking into feasibility and safety of sleeve gastrectomy in the 
perioperative period after liver transplant is currently recruiting patients and is 
expected to be completed by 2018 (Clinical trials identifier NCT02068872). 
 
There are case reports of bariatric surgery following liver transplant. In one 
study,  two patients underwent Roux-en-Y bypass for recurrent NASH in the 
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context of obesity which resulted in significant weight reduction, and 
improvement in hyperglycaemia and liver function tests [98]. In another study 
patients had Roux-en-Y bypass 26 months after liver transplant for cirrhosis 
(causes were hepatitis C (n=4), jejunal bypass surgery (n=1), 
haemangioendothelioma (n=1) and alcoholic liver disease (n=1)).  All patients 
had diabetes, four had hypertension and six had dyslipidaemia.  Two of the 
hepatitis C patients died due to multi-organ dysfunction syndrome and 
metastatic oesophageal cancer. In the surviving patients, there was a significant 
improvement in glycaemic control, reduction in BMI, and improved HDL levels 
[94]. The challenges of bariatric surgery in the transplant recipient are clear, but 
given the rising global burden of obesity it will undoubtedly become a more 
common occurrence.  
 
2.2.3 NAFLD and age 
 
In patients aged over 65 years, NASH is the most frequent indication for liver 
transplant [99] and notably age has been shown to be an independent predictor 
of poorer post-transplant outcomes [100].  According to a multivariable risk 
model to predict five-year survival in a large UK audit, for every one year of 
increased age, the hazard ratio is 1.01 [101]. As life expectancy continues to 
increase it is likely that older patients, who are likely to have more 
cardiovascular comorbidities, will be considered for transplantation, and thus 
input from geriatricians will be invaluable in relation to their cognitive function, 
functional state and risk of malignancy [100].  
 
2.2.4 NAFLD and diabetes 
 
NAFLD is closely associated with diabetes, which as with age has been 
independently associated with poor post-transplant survival, usually due to 
cardiovascular complications [102]. Studies show that patients with diabetes 
undergoing liver transplant have a longer length of hospital stay, higher 30 day 
re-admission rates[103], and greater incidence of renal dysfunction [104] and 
infection [105]. One study showed that patients with diet-controlled diabetes 
had comparable one and five year patient and graft survival to patients without 
diabetes, whereas outcomes were progressively worse for those on oral 
hypoglycaemic agents and insulin therapy [106]. Thus in patients with diabetes, 
optimisation of glycaemic control is advisable prior to transplant although there 
is no evidence yet that this alters outcomes.  
 
Intraoperative glucose control is important; Parks et al found an association 
between intraoperative hyperglycaemia (>11.1mmol/l) during liver transplant 
and immediate postoperative infection (RR 2.25, confidence interval 1.26-4.03) 
[107]. Similarly, Amorri et al found that patients with uncontrolled 
intraoperative hyperglycaemia had a higher rate of infections at 30 days 
postoperatively compared to those with blood glucose levels <8.3mmol/l (48% 
vs 30%) [108]. However, intensive glycaemic control increases the risk of having 
life-threatening hypoglycaemia. In view of previous studies suggesting higher 
mortality for patients with intensive glycaemic control targets (4.5-6mmol/l) vs 
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conventional (<10mmol/l) targets, for example in the NICE-SUGAR trial, 
moderately tight glycaemic control (6-10mmol/l) is recommended [109]. 
 
2.4 Selecting appropriate donor grafts 
 
As the prevalence of NAFLD is increasing, the proportion of donor grafts with 
steatosis is rising in parallel. It is now estimated that 10% of donors have 
steatosis greater than 30%. Graft steatosis has been shown to induce harmful 
microcirculatory and cellular changes, which can result in hepatocyte necrosis. 
Furthermore, steatosis impairs the regenerative capacity of the donor 
hepatocytes and has been associated with intrahepatic cholestasis and transient 
hyperbilirubinaemia post-transplant [110-113]. Grafts with greater than 30% 
steatosis have a significantly higher incidence of primary graft failure compared 
to those with less than 30% steatosis (13% vs <5%) [114, 115]. Donor grafts 
with more than 60% steatosis are often discarded, and even grafts with 30-60% 
steatosis are associated with reduced graft survival and higher patient mortality 
and hence are seldom used [116]. However, other donor characteristics are also 
important. One group recently reported that even with grafts obtained after 
brain death, provided cold ischaemia time was minimised (median 384 minutes), 
three year survival was comparable for grafts with steatosis<60% (n=354) and 
>60% steatosis (n=19) [117]. 
 
Static cold storage is widely used for organ preservation, however, steatotic 
livers have been shown to deteriorate quickly during hypothermic static 
preservation, mediated by a reduction in availability of adenosine triphosphate 
(ATP), with adverse outcomes [118]. An alternative technique, machine 
perfusion, aims to simulate a more physiological environment, with a continuous 
supply of nutrients and oxygen to the donor organ, and is associated with 
superior organ preservation in steatotic livers [119]. Furthermore, it allows a 
degree of resuscitation of pre-damaged organs, which offers the potential to use 
more marginal donors. Phase I trials of liver transplantation following 
normothermic machine perfusion suggest that it is safe and feasible [120]. 
 
Although liver biopsy is the gold standard for detecting steatosis, in cases of 
deceased liver donors, there may not be sufficient time to wait for the biopsy 
result. CT, Magnetic Resonance Imaging (MRI) and ultrasound are potential 
modalities used to quantitate the degree of steatosis. However, ultrasound  is 
operator dependent, MRI is expensive and CT has associated radiation risks. 
Furthermore, these methods cannot simultaneously assess fibrosis and steatosis. 
Use of Controlled Attenuation Parameter as part of transient elastography can 
overcome these problems, and has been shown to be particularly useful in 
quantifying smaller degrees of steatosis [121].  
 
3. Post-transplant considerations: 
 
3.1 Post-transplant outcomes 
 
US National Registry Data from the Scientific Registry of Transplant Recipients 
(SRTR) and UNOS indicate that for patients with NAFLD receiving a liver 
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transplant, one year survival is 84-89%, three year survival is 78-85%, five year 
survival is 77-84%, and ten year survival is 84% [8, 122, 123]. Other studies 
have reported that survival rates up to ten years are similar for patients 
receiving transplants for NAFLD and those receiving transplants for other 
indications (cryptogenic cirrhosis, HCV, alcoholic cirrhosis, cholestatic liver 
disease, and autoimmune liver disease) [8, 124].  It is important to remember 
that the patients who receive a transplant for NAFLD cirrhosis likely already a 
selected cohort, and that these results cannot be extrapolated to all patients with 
NAFLD who are considered for transplant.  
 
However, the likely cause of death differs for patients with NAFLD, being more 
likely to be cardiovascular disease  (OR 1.65; 95% CI, 1.01–2.70; p = 0.05) and 
sepsis (OR, 1.71; 95% CI, 1.17–2.50; P = .006), and less likely to be graft failure 
(OR, 0.21; 95% CI, 0.05–0.89; P =0.03) [125]. The increase in transplantation for 
NASH cirrhosis in the US has been paralleled by an increase in cardiovascular 
mortality following liver transplant. Therefore, clinicians must be vigilant for 
identifying and aggressively treating post-transplant cardiovascular 
complications.  
 
The peri-operative period is critical; some studies have shown that the 30-day 
mortality for patients with NAFLD is relatively high (8.5% in NAFLD patients, 
and 4.2% in patients without NAFLD), with death mainly related to infections 
and cardiac disease [126-128]. In a study by Van Wagner et al, patients with 
NASH cirrhosis had a higher incidence of cardiovascular events compared to 
those with alcoholic cirrhosis in the first year post-transplant, (26% vs 8%), 
particularly in the first 30 days post-transplant [129]. Over 50% of the patients 
who had a cardiovascular event had underlying cardiovascular risk factors such 
as high cholesterol or hypertension, yet only 17% and 13% of these patients 
were on aspirin and a statin respectively. In another study evaluating 5057 
patients with NASH cirrhosis undergoing liver transplant, Van Wagner et al 
showed that the association between NASH cirrhosis and postoperative cardiac 
mortality was no longer significant after controlling for diabetes, renal 
impairment and pre-existing cardiovascular disease [73]. The increased 
cardiovascular mortality post-transplant can therefore be attributed to the high 
frequency of cardiovascular risk factors in patients with NASH cirrhosis.  
 
3.2 Disease recurrence 
 
NAFLD often recurs post-transplant, which is likely because following transplant, 
reduced mobility and commonly used immunosuppression regimens place 
patients at higher risk of developing obesity, diabetes and hypertension, or 
exacerbating these conditions that were previously present [124].  
 
Diagnosing disease recurrence can be difficult as histology of the liver graft post-
transplant may be affected by complications of the transplant itself, such as 
rejection, biliary complications and nodular regenerative hyperplasia [130].  
 
A number of single-centre studies have tried to determine the incidence of 
recurrence [85, 124, 131-136], with between 8.2-92% of patients developing 
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recurrent NAFLD, 4-71.4% developing NASH, and 0-71.4% developing severe 
fibrosis by five years, with variable follow up periods ranging from a few weeks 
to 20 years.  
 
NAFLD recurrence correlates significantly with higher pre- and post-transplant 
BMI, post-transplant triglyceride levels, and higher post-operative steroid doses 
[132, 134, 135, 137]. A study showed that the single nucleotide polymorphism 
(rs738409 on PNPLA3 gene, which mediates triglyceride hydrolysis) influences 
NAFLD recurrence risk [137].  Multivariate regression analysis revealed that 
transplant recipients with the rs738409-GG genotype had a 13.7-fold higher risk 
of graft steatosis than those with the rs738409-CC genotype, independent of age 
and post-operative weight gain. 
 
Overall, up to ten-tears follow up, patients with NAFLD recurrence have patient 
and graft survival comparable to those transplanted for alcoholic liver disease, 
primary biliary cirrhosis and primary sclerosing cholangitis, suggesting that on 
the basis of current data recurrent NAFLD is not a major concern, at least in the 
medium term [131-133]  
 
3.3 Development of de novo NAFLD 
 
3.3.1 Incidence and diagnosis 
 
Patients who have undergone liver transplantation are at risk of developing 
NAFLD de novo [138] with an incidence of 18-33% [139-142]. Liver biopsy is 
important for diagnosis of de novo NAFLD, as blood tests and imaging cannot 
reliably identify the presence of NASH and degree of fibrosis. In a study of 599 
transplant recipients 31% of patients had de novo NAFLD after 40 months follow 
up, with NASH seen in 3.8% and advanced fibrosis or cirrhosis in 2.25%. Notably, 
51% of these patients had unremarkable liver function tests [142].  
 
3.3.2 Aetiology of de novo NAFLD post-transplant 
 
Both host and graft factors are likely to play a role in the development of NAFD 
post-transplant.  Post-transplant steatosis is associated with obesity, tacrolimus 
use, diabetes mellitus, hyperlipidaemia, arterial hypertension, alcoholic cirrhosis 
pre-transplant, and pre-transplant liver graft steatosis, with the prevalence of 
steatosis related to the number of these factors that are present [142, 143].  
 
Patients following transplant are more likely to develop features of the metabolic 
syndrome [138, 139, 144, 145], with the incidence of metabolic syndrome 
increasing from 5% pre-transplant to 52% following liver transplant [145]. 
Following transplant, an estimated 65-70% of patients develop hypertension 
post-transplant [146], one third of patients become obese [147, 148], and 5-30% 
of patients develop de novo diabetes. Immunosuppression can contribute to the 
development of the metabolic syndrome, with both tacrolimus and ciclosporin 
also associated with nephrotoxicity, which contributes to cardiovascular risk 
[149]. Tacrolimus is directly associated with diabetes and NAFLD [150, 151], 
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whereas ciclosporin is associated with hypertension and hyperlipidaemia [152]. 
Steroids are associated with diabetes, hypertension and obesity. 
 
The incidence of diabetes, obesity and graft steatosis post-transplant has been 
related to polymorphisms on the PNPLA3 gene of the transplant recipient [137, 
153]. A polymorphism in interleukin 28B has also been associated with 
development of the metabolic syndrome post-transplant, but the mechanisms 
are less clear [154]. 
 
It is possible that the relationship between alcoholic liver cirrhosis pre-
transplant, and NAFLD after transplant may also be because patients with 
alcoholic liver disease often also have NAFLD but because of the history of 
alcohol excess, the diagnosis of NAFLD was not fully considered pre-transplant. 
 
3.3.3 Protective factors against de novo NAFLD post-transplant 
 
Seo et al performed an analysis of 68 patients undergoing liver transplant, and 
found that use of ACE-inhibitors was associated with a lower risk of de novo 
NAFLD post-transplant (OR 0.09, 95% CI 0.01-0.92, p=0.042)[139], however, 
further data are required before recommending use of ACE inhibitors for NAFLD 
prevention. There is also concern that ACE inhibitors may worsen the 
hyperkalaemia associated with use of calcineurin inhibitors [155].  
 
3.3.4 Consequences and evolution of de novo NAFLD post-transplant 
 
Whilst hepatic steatosis does not predict post-transplant survival, patients that 
develop NAFLD are more likely to have cardiovascular events [156, 157]. 
 
In a study of patients who developed de novo NAFLD post-transplant, 13% 
regressed completely, 35% had a reduction of steatosis, 22% remained static and 
30% developed worsening of the steatosis [142]. The median time between first 
and last biopsies was only 38 months (6-60 months), and thus data regarding 
long-term outcomes is required. 
 
3.4 Management of NAFLD post-transplant 
 
3.4.1 Choosing an appropriate immunosuppression regime 
 
Choosing an appropriate immunosuppression regime requires weighing up the 
risk of unwanted side effects against the risk of graft rejection. Current regimens 
commonly involve combinations of steroids, calcineurin inhibitors, mTOR 
inhibitors and antimetabolites. The exact regimen will also be tailored according 
to the individual’s risk of rejection, presence of renal impairment and presence 
of liver cancer. 
 
Following a meta-analysis including 19 randomised controlled trials, Segev et al 
report that steroid-free regimens (where steroids were used ≤3months, or not at 
all) were associated with reduced relative risk of diabetes (RR 0.29, p<0.001), 
lower cholesterol levels (standard mean difference -0.41, p<0.001) and reduced 
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incidence of CMV infection (RR 0.52, p=0.001) with no impact on mortality, graft 
loss or infection rates [158]. Therefore UK guidelines recommend consideration 
of either a steroid-free regimen or early steroid withdrawal within three months 
[13].  
 
Whilst tacrolimus and ciclosporin are associated with features of the metabolic 
syndrome, immunosuppression regimens free of calcineurin inhibitors are 
associated with a higher risk of graft rejection [159].  Tacrolimus is generally 
preferred over ciclosporin because it is associated with better patient outcomes, 
although it is important to monitor tacrolimus levels (5-8ng/ml) to achieve a 
balance between therapeutic effect and toxicity [160]. Use of mycophenolate 
rather than azathioprine allows use of a reduced tacrolimus dose, although there 
are concerns about a possible greater risk of late infective episodes [161]. 
 
3.4.2 Treatment of NAFLD post-transplant 
 
There are no licensed treatments for NAFLD at present, and consequently there 
are no specific therapies to be considered for patients with NAFLD post-
transplant. Current management includes control of diabetes, hypertension, high 
cholesterol and obesity. If specific treatments are developed for NAFLD, 
consideration will need to be given to possible interactions with 
immunosuppressant medications.  
 
 
3.4.3 Post-transplant monitoring 
 
Regular monitoring is important to detect disease recurrence and assess graft 
function. Imaging and biomarkers cannot reliably distinguish hepatitis steatosis 
from NASH [162-164], however, the need for liver biopsy needs to be weighed 
up against the procedural risks. Therefore, UK guidelines suggest that post-
transplant patients have regular USS (initially at one year and then every two 
years), with liver biopsy recommended if the liver is found to be echo-bright 
[13]. 
 
It is also important to monitor and treat patients for features of the metabolic 
syndrome, by monitoring blood pressure, glycaemic control and lipid profile, 
with a target LDL cholesterol level <2.6mmol/L [13, 165]. 
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4. Summary and Conclusions 
 
 
NASH cirrhosis is becoming an increasingly common reason for liver transplant. 
The development of NAFLD, risk of recurrent NAFLD after transplant, and 
development of de novo NAFLD in patients transplanted for other reasons are all 
closely linked to the metabolic syndrome.  Based on a thorough literature review, 
we present the following recommendations and suggestions for further work: 
 
Careful evaluation of patients’ cardiovascular risk factors pre-transplant is 
essential.  
 
Patients with NAFLD often have features of the metabolic syndrome. All patients 
should have an ECG, ECHO, CXR and assessment of functional capacity. Patient 
with cardiovascular risk factors should have non-invasive testing and early 
discussion with a specialist to decide on the appropriateness of coronary 
angiography.  Patients with pre-existing features of the metabolic syndrome 
should have these optimised prior to transplant.   
 
The most cost-effective method of non-invasive screening for occult CAD needs 
to be established through further studies. Although PCI is feasible in advanced 
liver disease, there are increased bleeding risks in the coagulopathic patient. 
CABG should be avoided in advanced liver disease. Randomised controlled trials 
are needed to assess what degree of stenosis merits intervention for CAD pre-
transplant, and whether this actually influences postoperative outcomes.  Future 
developments may include consideration of screening for genetic 
polymorphisms that put patients at additional risks thus promoting a 
personalised approach. 
 
Patients with renal dysfunction should be identified prior to transplant, and SLK 
transplant should be considered if appropriate 
 
Pre-operatively all patients should have measurement of serum creatinine, 
urinalysis, quantitative protein measurement and renal ultrasound. If these are 
abnormal, isotopic measurement of GFR may be helpful. In the acute setting, in 
patients with renal dysfunction, serum creatinine should be measured daily. 
Based on the clinical and laboratory data pre-operative dialysis should be 
considered. SLK transplant should be considered in: (1) patients with end stage 
renal disease requiring a liver transplant (2) patients with acute kidney injury 
(serum creatinine >2mg/dL) on dialysis for over eight weeks (3) patients with 
chronic kidney disease with >30% interstitial fibrosis or >30% global 
glomerulosclerosis on renal biopsy. 
 
Post-operatively, monitoring of calcineurin inhibitors is important to avoid 
nephrotoxicity. In view of the multiple possible aetiologies of renal impairment 
post-operatively, it is also important to control fluid balance, blood pressure and 
blood glucose.  
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Further work is needed to optimise methods of assessing renal dysfunction in 
the context of liver cirrhosis, as serum creatinine tends to overestimate GFR in 
this group. 
 
3. Avoid arbitrary BMI cut off values in assessing patients who are overweight 
 
Patients should be assessed by a dietician and should only lose weight under 
specialist supervision. Clinicians should be vigilant for sarcopaenic obesity. In 
future, bariatric surgery may play a greater role in the management of NAFLD- 
both in prevention and treatment.  
 
It is not yet clear when is the best time to perform surgery, what type of surgical 
technique is best, and in which subset of patients this is likely to be most helpful. 
Data is mainly from case series, and randomised controlled trials in this area are 
needed. Further work could also explore the potential of newer weight loss 
procedures, such as endobarrier. 
 
4. Maintain moderate glycaemic control in the perioperative period 
 
Clinicians should aim to maintain blood sugars of 6-10mmol/l, particularly 
around the time of surgery, to reduce the risk of postoperative infections, whilst 
avoiding hypoglycaemia. 
 
Further studies are needed to establish whether pre-operative improvement of 
poor glycaemic control in diabetic patients influences postoperative outcomes. 
 
5. Be vigilant for development of the metabolic syndrome postoperatively 
 
Patients with NASH cirrhosis are at high risk of cardiovascular events in the 
post-operative period. Features of the metabolic syndrome may worsen with 
post-operative immobility and immunosuppression.  Patients with NAFLD are 
also more likely to suffer worsening renal function. Post-operatively, patients 
should have regular monitor and treatment of blood pressure, glycaemic control, 
lipid profile and renal function. Steroid-free immunosuppression regimes should 
be considered and where they are used, early withdrawal is recommended.  
 
Further studies should establish optimal immunosuppression regimes in this 
group. 
 
6. Biopsy is required to establish a diagnosis of NAFLD recurrence 
 
Histology can help to detect recurrence of NAFLD or development of NAFLD de 
novo. Some pharmacological agents, such as vitamin E, may be useful in the 
treatment of NAFLD but their use in the post-transplant setting has not been 
studied and represents an area of further work. Further work is also needed to 
establish the long-term outcomes of NAFLD, both in patients who develop 
recurrent disease and in those who develop de Novo disease after transplant. 
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Authors Study 
Design 
       Population       Findings 
Perez-Protto et al 
(2013) [166] 
Single 
Centre Study 
       Normal weight, n=183 (BMI 20-26) 
       Obese, n=47 (BMI>38) 
No significant difference in patient or graft 
survival 
Dare et al (2014)        
[167] 
Single centre 
study 
Underweight, n=8 (BMI<18.5) 
Normal weight, n=52 (BMI 18.5-24.9) 
Overweight, n=50 (BMI 25-29.9) 
Obese, n=53 (BMI 30- 34.9) 
Severely obese, n=18 (BMI 35-39.9) 
Morbidly obese, n=11 (BMI>40) 
Increased rate of peri-operative complications 
and length of stay in obese group (p<0.001) 
No significant difference in patient or graft 
survival 
Tanaka et al (2013)  
[91] 
Single centre 
study 
Underweight, n=58 (BMI<18.5) 
Normal weight, n=151 (BMI 18.5-24.9) 
Overweight, n=160 (BMI 25-29.9) 
Obese, n=92 (BMI 30- 34.9) 
Severely obese, n= 31 (BMI 35-39.9) 
Morbidly obese, n=15 (BMI>40) 
Higher mortality and graft failure rate in both 
underweight and morbidly obese groups (p= 
0.010 and p=0.038) 
No significant diference in length of ICU stay, 
length of hospital stay and postoperative vascular 
complications 
Conzen et al (2015)   
[83] 
Single centre 
study 
Underweight, n=8 (BMI<18.5) 
Normal weight, n=52 (BMI 18.5-24.9) 
Overweight, n=50 (BMI 25-29.9) 
Obese, n=53 (BMI 30- 34.9) 
Severely obese, n=18 (BMI 35-39.9) 
Morbidly obese, n=11 (BMI>40) 
No significant difference in ICU or hospital length 
of stay, operating time, or perioperative 
complications 
Morbidly obese patients had significantly lower 5 
year graft (p<0.02) and patient survival (p<0.01) 
Singhal et al (2015)  
[168] 
Cohort, 
using SRTR 
database 
      Not morbidly obese, n= 12606 (BMI<40) 
      Morbidly obese, n=416 (BMI>40) 
Longer length of stay in morbidly obese patients 
(p<0.0001), but no significant difference in 
readmission rate 
No significant difference in graft or patient 
survival at 2 years 
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Schaeffer et al 
(2009) [169] 
Single 
Centre Study 
Non-obese, n=143 (BMI<30) 
Moderate obesity, n=14 (BMI 30-34) 
Severe obesity, n=10 (BMI>35) 
Severely obese patients had a higher incidence of 
wound infections and dehiscence (p=0.0001) 
No significant difference in graft or patient 
survival at 1 year 
Orci et al (2013)        
[92]  
Cohort, 
using SRTR 
database 
Underweight, n=952 (BMI<18.5) 
Normal weight, n=11430 (BMI 18.5-24.9) 
Overweight, n=13354 (BMI 25-29.9) 
Obese, n= 7786 (BMI 30- 34.9) 
Severely obese, n=3363 (BMI 35-39.9) 
Morbidly obese, n= 1308 (BMI>40) 
Underweight patients had significantly lower 
post-operative survival rates 
Hakeem et al (2013) 
[170] 
Single 
Centre Study 
Underweight, n=47 (BMI<18.5) 
Normal weight, n=643 (BMI 18.5-24.9) 
Overweight, n=417 (BMI 25-29.9) 
Obese, n=145 (BMI 30-34.9) 
Morbidly obese, n=73 (BMI>35) 
No signification difference in patient graft 
survival across groups 
Prolonged length of stay in morbidly obese 
patients (p<0.001) 
LaMattina et al 
(2012) [82] 
Single 
Centre Study 
Normal weight, n=216 (BMI 18-25) 
Overweight, n=266 (BMI 25.1-30) 
Class I obese, n=176 (BMI 30.1-35) 
Class II obese, n=83 (BMI 35.1-40) 
Class III obese, n=47 (BMI>40) 
No signification difference in patient or graft 
survival across groups 
Prolonged operation time, higher use of blood 
products, longer ICU length of stay and more 
frequent infectious complications in obese 
patients 
Werneck et al 
(2011) [171] 
Single 
Centre Study 
Normal weight, n=46 (BMI 18.5-24.99) 
Overweight, n=58 (BMI >30) 
No significant difference in patient survival 
across groups 
No significant difference in ICU length of stay or 
necessity of NIV 
Nair et al (2002)        
[90] 
Cohort, 
using UNOS 
database 
Non-obese, n=68 
Obese (F BMI 27.3-32.3, M BMI 27.8- 31.1 
Severely obese (F BMI>32.3, M BMI>31.1 
Higher rate of primary non-function of graft, 
immediate mortality, 1-year mortality, 2-year 
mortality, 5-year mortality in morbidly obese 
group (p<0.05)  
Dick et al (2009)       
[172]  
Cohort, 
using UNOS 
database 
Underweight, n=1827 (BMI<18.5) 
Control, n=68172 (BMI 18.5-40) 
Severely obese, n=1447 (BMI>40) 
Being underweight or severely obese was 
associated with greater risk of death (p<0.0001) 
Leonard et al (2008) 
[87] 
NIDDK Liver 
Transplant 
Underweight, n=67 (BMI<18.5) 
Normal weight, n=561 (BMI 18.5-25) 
No significant difference in patient or graft 
survival across groups 
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Table 1- Summary of studies investigating the impact of obesity on liver transplant outcomes
Database Overweight, n=405 (BMI 25.1-30) 
Class I obese, n=178 (BMI 30.1-35) 
Class II obese, n=69 (BMI 35.1-40) 
Class III obese, n=33 (BMI>40) 
Boin et al (2007)       
[173] 
Single centre 
study 
Non-obese, n=38 (BMI<30) 
Obese, n=206 (BMI>30) 
No  significant difference in patient or graft 
survival across groups 
Fujikawa et al 
(2006) [174] 
Single 
Centre Study 
Non-obese, n=288 (BMI<25) 
Obese, n=245 (BMI 25-30) 
Morbidly obese, n=167 (BMI >30) 
No  significant difference in patient or graft 
survival across groups 
Hillingso (2005)        
[175] 
 
Single 
Centre Study 
Non-obese, n=20 (BMI<30) 
Obese , n=20 (BMI>30) 
Obese patients had a higher patient mortality 
rate (p<0.01) 
No differences across the groups in length of ICU 
stay, use of blood products, or duration of 
operation 
Sawyer et al (1999)  
[176] 
Single 
Centre Study 
Non-obese, n=202 (BMI <30) 
Obese, n=49 (BMI 30-34) 
Severely obese, n=26 (BMI >35) 
Severely obese patients had higher rates of 
wound infection  (p=0.0001) and death 
attributible to multisystem organ failure 
(p=0.0001) 
No significant difference in overall survival 
Braunfeld et al 
(1996)[ 177] 
Single centre 
study 
Non-obese, n=61 (BMI<30) 
Obese, n=40 (BMI>30) 
No  significant difference in patient or graft 
survival, or post-operative complications across 
groups 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Figure 1. Recommended pathway for pre-operative evaluation of cardiovascular 
risk in patients undergoing liver transplant. (CPEX: cardiopulmonary exercise 
testing, ECHO: echocardiogram, CT: computerised tomography, ECG: 
electrocardiogram, CXR: chest x-ray) 
 
 
